Blood sugar (HbA1c) and contrast sensitivity

If you live with diabetes, you already track a number that summarises months of blood-sugar control: your HbA1c. It is the workhorse of diabetes management. What is less well known is that another number — how well you see low-contrast patterns — can shift in diabetes before the classic signs of eye disease appear on a dilated exam. This post is about the connection between the two: what the evidence shows, what it means, and what it very much does not.

We have written before about the early contrast signs of diabetic retinopathy. This post narrows in on the glycemic-control side of the story — the HbA1c question specifically.

TL;DR. In diabetes, contrast sensitivity is often reduced before diabetic retinopathy is visible on a standard eye exam, likely reflecting early retinal neurodegeneration that precedes the blood-vessel damage clinicians look for (Silva-Viguera et al., 2023). Long-term blood-sugar control matters: landmark trials (DCCT, 1993; UKPDS, 1998) proved that lower HbA1c substantially reduces the risk of retinopathy developing and progressing. A contrast sensitivity test is a screening signal you can track between eye appointments — never a replacement for the dilated exam that actually detects and stages retinopathy.

Why diabetes affects contrast vision early

The eye complication most people associate with diabetes is diabetic retinopathy — damage to the small blood vessels of the retina, which is why a dilated exam looks for microaneurysms, haemorrhages, and abnormal vessels. That vascular picture is real and important. But it is not the whole story, and it may not be the first thing that happens.

A growing body of work describes diabetic retinal neurodegeneration — dysfunction and loss of retinal neurons and their connections — as an early event that can precede, and partly drive, the visible vascular changes. The retina is metabolically demanding nervous tissue, and chronically elevated glucose stresses it in ways that show up as functional deficits before structural ones. Contrast sensitivity, colour discrimination, and the electroretinogram can all register change while the fundus still looks clean.

That is the mechanistic reason contrast sensitivity is interesting in diabetes: it probes retinal function, and function can slip before the vessels visibly break down. It is a different kind of measurement from the one your ophthalmologist makes when they photograph or examine the retina — complementary, not redundant.

What the evidence shows

The literature on contrast sensitivity in diabetes is substantial and reasonably consistent at the group level.

Contrast sensitivity is reduced in diabetes, including before retinopathy. A 2023 systematic review by Silva-Viguera and colleagues pooled 21 studies and found that contrast sensitivity loss is associated with diabetes and diabetic retinopathy — and, importantly, that people with diabetes but without visible retinopathy also showed contrast sensitivity reductions, though not uniformly across every study. Their conclusion was direct: the changes "suggest that there is damage to the retina prior to the vascular ones and that they could be detected by this test" (Silva-Viguera et al., 2023). That is the core claim — a functional signal that can lead the structural one.

The signal is a group-level pattern, not a personal diagnostic. "Reduced on average in a study population" does not mean every person with diabetes will show a contrast deficit, nor that a deficit proves retinal disease. Contrast sensitivity has many other causes — uncorrected refractive error, cataract (which is also more common in diabetes), dry eye, ordinary aging. The measurement is a sensitive but non-specific probe.

Blood-sugar control changes the risk of the underlying disease. This is where HbA1c enters directly. Two landmark randomised trials settled the question of whether tighter glycemic control protects the eyes. The Diabetes Control and Complications Trial (DCCT) in type 1 diabetes showed that intensive glucose control markedly reduced the development and progression of retinopathy compared with conventional treatment (DCCT Research Group, 1993). The UK Prospective Diabetes Study (UKPDS 33) showed the same protective relationship in type 2 diabetes: lower HbA1c meant fewer microvascular complications, including retinopathy (UKPDS Group, 1998). The relationship between long-term glucose exposure and retinal risk is one of the best-established facts in diabetes medicine.

Put the two threads together and the honest synthesis is this: HbA1c is a strong, proven lever on your risk of the disease that damages retinal function; contrast sensitivity is a functional readout that can move early in that process. What the literature does not claim is that your contrast sensitivity score tracks your HbA1c week to week like a mood ring. The connection is through the slow accumulation of glycemic exposure and its effect on retinal tissue, not a fast, tight coupling.

How a home contrast test fits into diabetes care

The framing is the same one we use for every condition: a screening signal, a tracking tool, and a conversation-starter — never a diagnosis.

A baseline and a trend. If you have diabetes and your eyes have been clean so far, a contrast sensitivity result taken on the same device in the same lighting gives you a functional anchor. Repeated monthly, it produces a trend line — and a downward drift is the kind of thing worth mentioning to your eye doctor sooner rather than at the next annual exam. Our post on self-tracking vision in chronic illness covers how to keep that data honest.

A complement to HbA1c, not a substitute. These two numbers answer different questions. HbA1c tells you about average glucose control — the input. Contrast sensitivity tells you about one aspect of retinal function — a downstream output. Watching both gives you more texture than either alone. Neither replaces the dilated retinal exam.

A reason to keep the exam on the calendar. This is the non-negotiable part. Diabetic retinopathy is detected and staged with a dilated fundus examination and retinal imaging (fundus photography and OCT). The recommended screening schedule depends on your diabetes type and duration, but for most adults with diabetes it is at least annual, sometimes more often. A home contrast test does not change that schedule; if anything, a drifting result is a reason to move an appointment up, not to skip it.

What it cannot tell you

Note. A contrast sensitivity test is a screening signal of overall visual function. It does not diagnose diabetic retinopathy — or any other condition — and it cannot replace a dilated eye examination.

A normal contrast sensitivity result does not rule out diabetic eye disease. Retinopathy can be present, and even sight-threatening, with preserved contrast sensitivity — particularly if changes are outside the central retina. A clean result is reassuring, not exonerating.

A reduced result does not mean you have retinopathy. Refractive error (get your prescription checked first), cataract, dry eye, and normal aging all lower contrast sensitivity and are common in people with diabetes.

The test cannot stage retinopathy, cannot detect macular edema (a leading cause of vision loss in diabetes that requires OCT to see), and cannot substitute for the imaging your ophthalmologist uses. Any sudden change in vision — new blurring, floaters, a shadow — is a reason to call your eye doctor promptly, not to wait for a retest.

This post is educational and is not medical advice about managing your blood sugar. HbA1c targets are individual; set them with your physician.

Frequently asked questions

Can high blood sugar affect my vision before diabetic retinopathy shows up?

The evidence suggests it can affect retinal function early. Contrast sensitivity is reduced in many people with diabetes, sometimes before retinopathy is visible on an exam, consistent with early retinal neurodegeneration preceding the classic vascular changes (Silva-Viguera et al., 2023). Separately, large swings in blood sugar can temporarily blur vision by changing the shape and hydration of the eye's lens — a transient effect distinct from retinopathy.

Does lowering my HbA1c protect my eyes?

Yes — this is well established. The DCCT (type 1 diabetes) and UKPDS (type 2 diabetes) trials both showed that better long-term glucose control substantially lowers the risk of diabetic retinopathy developing and progressing (DCCT, 1993; UKPDS, 1998). Your individual HbA1c target should be set with your physician, since ideal targets vary by person.

Will my contrast sensitivity score go up if my HbA1c comes down?

Not in a fast, one-to-one way. The link between glycemic control and retinal health plays out over months and years of cumulative glucose exposure, not week to week. Contrast sensitivity is best used as a slow trend line, retested on the same device and lighting, rather than as an instant readout of today's blood sugar.

How often should I have a diabetic eye exam?

For most adults with diabetes, at least once a year, and sometimes more often depending on your diabetes type, duration, control, and any existing retinopathy. A home contrast test does not change this schedule — it is a between-visit signal, and a downward trend is a reason to move an appointment up, not to postpone it. Follow your ophthalmologist's specific guidance.

Is a home vision test a substitute for retinal screening?

No. Diabetic retinopathy and diabetic macular edema are detected and staged with a dilated exam and retinal imaging (fundus photography and OCT). A contrast sensitivity test measures one aspect of function; it cannot see the retina or detect edema. Use it alongside screening, never instead of it.

Take the test

If you have diabetes, a functional baseline on the contrast axis is a small, free thing you can do today and repeat over time.

Take the test now. It runs in your browser in about three minutes. Save the number, retest monthly on the same device, and bring the trend to your diabetic eye exam. See the methodology page for how it is calibrated and our post on the early contrast signs of diabetic retinopathy for the vascular side of the picture. A screening signal to inform your care — never a replacement for the dilated exam.

References

• Silva-Viguera, M.-C., García-Romera, M.-C., López-Izquierdo, I., De-Hita-Cantalejo, C., Sánchez-González, M. C., & Bautista-Llamas, M.-J. (2023). Contrast Sensitivity Assessment in Early Diagnosis of Diabetic Retinopathy: A Systematic Review. Seminars in Ophthalmology, 38(4), 319–332. Systematic review of 21 studies finding contrast sensitivity loss in diabetes, including in eyes without visible retinopathy — evidence that functional retinal change can precede vascular change.
• The Diabetes Control and Complications Trial (DCCT) Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329(14), 977–986. Landmark type 1 trial showing intensive glucose control markedly reduces retinopathy development and progression.
• UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352(9131), 837–853. Landmark type 2 trial establishing that lower HbA1c reduces microvascular complications, including retinopathy.
• Pelli, D. G., Robson, J. G., & Wilkins, A. J. (1988). The design of a new letter chart for measuring contrast sensitivity. Clinical Vision Sciences, 2, 187–199. The Pelli-Robson chart — the clinical instrument that anchors contrast-sensitivity measurement, including in diabetes research.